Printer Friendly

CollaGenex Pharmaceuticals to Conduct Second Quarter 2005 Earnings Conference Call on August 2.

NEWTOWN, Pa. -- CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today announced that it will hold a conference call on Tuesday, August 2, 2005, at 11:00 a.m. Eastern Daylight Time to discuss the Company's second quarter 2005 financial results. A press release announcing the Company's financial results will be released before the market opens on Tuesday, August 2, 2005.

Colin Stewart, president and chief executive officer of CollaGenex, and Nancy C. Broadbent, chief financial officer of CollaGenex, will host the conference call.

Investors and other interested parties may access the conference call by dialing (888) 394-8045 in the U.S. or (973) 409-9260 internationally, or via a live Internet broadcast on the company's website at www.collagenex.com.

For those who cannot listen to the live broadcast, a replay will be available shortly after the call at www.collagenex.com for 90 days. Additionally, a recording of the call will be available by telephone until 11:59 p.m. on August 9, 2005 by dialing (877) 519-4471 in the U.S. or (973) 341-3080 internationally, and entering access code 6277476.

About CollaGenex

CollaGenex Pharmaceuticals, Inc. is a specialty pharmaceutical company that has built its reputation on providing innovative medical therapies to the dental and dermatology markets. CollaGenex currently sells Periostat(R) as the first and only pharmaceutical to treat periodontal disease by inhibiting the enzymes that destroy periodontal support tissues and by enhancing bone protein synthesis. The company also sells Atridox(R), Atrisorb FreeFlow(R) and Atrisorb-D FreeFlow(R) for the treatment of adult periodontitis under a license from QTL USA, Inc., the successor to Atrix Laboratories, Inc. Its professional dermatology sales force markets Pandel(R), a prescription topical corticosteroid licensed from Altana, Inc. and also co-promotes Alcortin(TM) (1% iodoquinol and 2% hydrocortisone), a prescription topical antifungal steroid combination, and Novacort(TM) (2% hydrocortisone acetate and 1% pramoxine HCl), a prescription topical steroid and anesthetic, under a co-promotion agreement with Primus Pharmaceuticals, Inc.

Research has shown that certain unique properties of the tetracyclines discovered during the development of Periostat may be applicable to other diseases involving inflammation and/or destruction of the body's connective tissues. CollaGenex is further evaluating certain IMPACS compounds, including Oracea and Col-3, to assess whether they are safe and effective in these other applications. The Company has a pipeline of innovative product candidates with possible applications in dermatology and other disease states. In addition, CollaGenex has acquired the Restoraderm(TM) technology, a unique, proprietary dermal drug delivery system, and plans to develop a range of topical dermatological products with enhanced pharmacologic and cosmetic properties.

To receive additional information on the Company, please visit our Web site at www.collagenex.com, which does not form part of this press release.

Periostat(R) is a registered trademark and Restoraderm(TM), IMPACS(TM) and Oracea(TM) are trademarks of CollaGenex Pharmaceuticals, Inc.

Pandel(R) is a trademark of Taisho Pharmaceuticals.

Atridox(R), Atrisorb(R) and Atrisorb-D(R) are registered trademarks of QLT USA, Inc.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Jul 19, 2005
Words:495
Previous Article:USANA Announces Record Second Quarter Sales and Profits.
Next Article:Experts Available to Discuss Steady Tourism Despite High Energy Prices.


Related Articles
CollaGenex Pharmaceuticals Reports Record Revenues of $14.1 Million and Net Income Allocable to Common Stockholders of $0.14 per Basic and Diluted...
CollaGenex Pharmaceuticals Reports Financial Results for the First Quarter of 2005.
CollaGenex Pharmaceuticals Reports Financial Results for the Second Quarter of 2005; New Drug Application (''NDA'') for Oracea(TM) filed with FDA on...
CollaGenex Pharmaceuticals Appoints Douglas A. Poedtke as Vice President of Sales.
CollaGenex Pharmaceuticals Reports Financial Results For the Third Quarter of 2005.
CollaGenex Pharmaceuticals to Host Fourth Quarter 2005 Earnings Conference Call on February 28th.
CollaGenex Pharmaceuticals Reports Financial Results For the First Quarter of 2006.
CollaGenex Pharmaceuticals to Host Second Quarter and First Half 2006 Earnings Conference Call on August 2nd.
CollaGenex Pharmaceuticals Reports Financial Results for the Second Quarter and First Half of 2006; Company Revises 2006 Financial Guidance to...
CollaGenex Pharmaceuticals to Host First Quarter 2007 Financial Results Conference Call on May 2nd.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters